Intra-Cellular Therapies Inc.(ITCI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ITCI Intra-Cellular Therapies Inc.

停牌 04-01 16:00:00 EDT

131.87

+0.00

0.00%

最高131.87	最低131.87	成交量0.00
今开131.87	昨收131.87	日振幅0.00%
总市值140.21亿	流通市值138.23亿	总股本1.06亿
成交额21.19亿	换手率0.00%	流通股本1.05亿
市净率12.21	ROE-8.58%	每股收益-0.72
52周最高131.98	52周最低64.09	市盈率-182.12
股息0.00	股息收益率0.00	ROA-6.96%

北京优虎网络科技有限公司

{"stockData":{"symbol":"ITCI","market":"US","secType":"STK","nameCN":"Intra-Cellular Therapies Inc.","latestPrice":131.87,"timestamp":1743537600000,"preClose":131.87,"halted":3,"volume":0,"delay":0,"floatShares":104819487,"shares":106327952,"eps":-0.724088,"marketStatus":"停牌","change":0,"latestTime":"04-01 16:00:00 EDT","open":131.87,"high":131.87,"low":131.87,"amount":2118507571.61162,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.724088,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":131.87,"volumeRatio":0},"requestUrl":"/m/hq/s/ITCI","defaultTab":"news","newsList":[{"id":"2514773078","title":"Intra-Cellular Therapies Inc.2024财年实现净利润-74.68百万美元，同比增加46.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514773078","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514773078?lang=zh_cn&edition=full","pubTime":"2025-02-25 00:00","pubTimestamp":1740412843,"startTime":"0","endTime":"0","summary":"2月25日，Intra-Cellular Therapies Inc.公布财报，公告显示公司2024财年净利润为-74.68百万美元，同比增加46.66%；其中营业收入为6.81亿美元，同比增加46.77%，每股基本收益为-0.72美元。从资产负债表来看，Intra-Cellular Therapies Inc.总负债2.18亿美元，其中短期债务4.23百万美元，资产负债比为6.28，流动比率为6.35。机构评级：截至2025年2月25日，当前有11家机构对Intra-Cellular Therapies Inc.目标价做出预测，其中目标均价为132.00美元，其中最低目标价为132.00美元，最高目标价为132.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225000058a25229a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225000058a25229a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ITCI"],"gpt_icon":0},{"id":"2513291216","title":"Needham：重申Intra-Cellular Therapies(ITCI.US)评级，由持有调整至持有评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513291216","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513291216?lang=zh_cn&edition=full","pubTime":"2025-02-22 02:34","pubTimestamp":1740162872,"startTime":"0","endTime":"0","summary":"Needham：重申Intra-Cellular Therapies(ITCI.US)评级，由持有调整至持有评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/22023448321216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ITCI"],"gpt_icon":0},{"id":"2513295915","title":"Intra-Cellular Therapies(ITCI.US)：2024年Q4财报实现营收1.992亿美元，前值为1.321亿美元，预期值为1.94亿美元；每股收益为-0.16美元，前值为-0.29美元，预期值为-0.12美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513295915","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513295915?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:23","pubTimestamp":1740147784,"startTime":"0","endTime":"0","summary":"Intra-Cellular Therapies(ITCI.US)：2024年Q4财报实现营收1.992亿美元，前值为1.321亿美元，预期值为1.94亿美元；每股收益为-0.16美元，前值为-0.29美元，预期值为-0.12美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/21222348320010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ITCI"],"gpt_icon":0},{"id":"1132963363","title":"Intra-Cellular Therapies 第四季度每股收益$(0.16) 不及预期$(0.11)，销售额$1.9922亿 超预期$1.934亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1132963363","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132963363?lang=zh_cn&edition=full","pubTime":"2025-02-21 21:43","pubTimestamp":1740145426,"startTime":"0","endTime":"0","summary":"Intra-Cellular Therapies报告季度每股亏损$，未达到分析师一致预期的$，差异为45.45%。公司报告季度销售额为$1.9922亿，超过分析师一致预期的$1.934亿，超出3.01%。相比去年同期销售额$1.321亿，这是50.81%的增长。以上内容来自Benzinga Earnings专栏，原文如下：Intra-Cellular Therapies  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 45.45 percent. This is a 44.83 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $199.22 million which beat the analyst consensus estimate of $193.40 mi","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Intra-Cellular Therapies 第四季度每股收益$(0.16) 不及预期$(0.11)，销售额$1.9922亿 超预期$1.934亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITCI"],"gpt_icon":0},{"id":"2507955925","title":"加拿大投资银行集团：下调Intra-Cellular Therapies(ITCI.US)评级，由买入调整至持有评级, 目标价由119.00美元调整至132.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507955925","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507955925?lang=zh_cn&edition=full","pubTime":"2025-01-31 18:34","pubTimestamp":1738319697,"startTime":"0","endTime":"0","summary":"加拿大投资银行集团：下调Intra-Cellular Therapies(ITCI.US)评级，由买入调整至持有评级, 目标价由119.00美元调整至132.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/31183447919769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ITCI"],"gpt_icon":0},{"id":"2504449484","title":"特朗普2.0时代即将开启，投资机会如何掘金？","url":"https://stock-news.laohu8.com/highlight/detail?id=2504449484","media":"招商基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504449484?lang=zh_cn&edition=full","pubTime":"2025-01-20 10:36","pubTimestamp":1737340585,"startTime":"0","endTime":"0","summary":"美国候任总统唐纳德·特朗普将于美东时间1月20日12时正式宣誓就任美国第47任总统。特朗普2.0时代即将开启，有哪些投资机会可以布局？值得一提的是，科技股在特朗普任期内表现尤为突出，成为推动美股上涨的主要力量。在特朗普第一个任期内，美元整体表现相对弱势。4年任期内，美元指数累计下跌了10.53%。而纵观全球市场，在特朗普上一任期内，恒生科技指数涨幅超过147%，表现甚至略微优于纳斯达克指数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DSGX","CHDN","INCY","REGN","MPWR","TW","FER","RGLD","MMYT","RVMD","ADBE","DOX","BRKR","LSCC","COO","NFLX","TSYW.SI","EXE","BK4588","NTES","QID","ERIE","QXO","NTRA","DASH","PCTY","MNDY","NVDA","BK4593","AAON","MKTX","NWSA","CDNS","EWBC","WDC","BIIB","PCVX","GTLB","CSCO","CWST","LU0757428866.USD","LIN","DDOG","AAL","LU2065731478.USD","POOL","NDAQ","CYBR","AGNC","MNST","CDW","ASML","INTC","LULU","CCEP","LSTR","MRNA","TPG","EVRG","CG","MTCH","MELI","TCOM","RYAAY","WWD","TTD","OLED","MANH","TER","BK4581","INTU","CHTR","BK4561","AMAT","FWONK","FOXA","TMUS","CHRW","ESLT","BSY","RGEN","DPZ","ROIV","ILMN","GOOGL","TEAM","ON","PEP","BKNG","PTC","AMD","GILD","RKLB","CSWI","LNW","MEDP","GRAB","APA","ENPH","LPLA","ADSK","HON","INSM","ODFL","SMCI","USJW.SI","MSFT","FYBR","ERIC","HOLX","TQQQ","ULTA","CINF","BPMC","OTEX","TLN","TSEM","TXN","BK4550","CHRD","LKQ","LNT","EBAY","CASY","CEG","MARA","AMGN","TTWO","KDP","ROST","JD","RADX","CME","BPOP","ZM","ISRG","PLTR","GEHC","HOOD","BK4086","NXPI","SIRI","CTSH","FTNT","FFIV","LU0053671581.USD","MRVL","PFG","QRVO","MTSI","PARA","HSIC","FTAI","LOGI","SAIA","CTAS","PODD","ALGN","CSX","BMRN","HBAN","JBHT","SRPT","MCHP","EXPE","RPRX","DOCU","DUOL","PAYX","COKE","ARM","CFLT","SNPS","ITCI",".IXIC","AEP","QCOM","LAMR","PNFP","EQIX","LI","LECO","GEN","FRPT","JKHY","NICE","QLD","OKTA","CPB","HST","AVGO","NTNX","AKAM","WYNN","ROKU","EA","STX","ALAB","CSGP","DLTR","PSQ","CHKP","SBAC","FOX","HLNE","SEIC","EXAS","NVIW.SI","ONC","NDSN","SWKS","TSCO","AUR","COST","Z","GMAB","TECH","GLPI","NVMI","WBA","ADI","ICLR","GNTX","ALNY","ORLY","CBSH","KHC","MDLZ","META","STLD","ROP","TSLA","SOFI","MDB","NTAP","MNQmain","AFRM","NBIX","TROW","AXON","TTEK","WTFC","PAA","ANSS","PDD","CPRT","HQY","MIDD","BK4534","FAST","SBUX","REG","DKNG","NQmain","RIVN","ZS","CZR","SQQQ","BK4585","IDXX","NTRS","BKR","FSLR","AAPL","LU1815336091.USD","FCNCA","COIN","SFM","PCAR","ENTG","AZN","CRWD","AMZN","SSNC","TRMB","HTHT","ARGX","USAW.SI","QQQ","MKSI","FSV"],"gpt_icon":1},{"id":"1139932042","title":"一周美股牛榜 | 遭强生收购，Intra-Cellular飙33%；比特币狂飙，MicroStrategy涨21%；SoFi涨17%，小鹏涨16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139932042","media":"老虎资讯综合","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139932042?lang=zh_cn&edition=full","pubTime":"2025-01-20 10:27","pubTimestamp":1737340045,"startTime":"0","endTime":"0","summary":"此次交易将使强生的产品组合中增加Intra-Cellular的Lumateperone，这是一种治疗双相情感障碍和精神分裂症的药物。比特币上涨，特朗普可能发布加密货币行政命令；MicroStrategy股价上涨21%在美国当选总统唐纳德·特朗普可能很快发布一项将加密货币列为国家优先事项的行政命令的消息传出后，比特币重新加入了加密货币的涨势。Hindenburg发布报告后的第二天，Carvana股价下跌超过11%，但随后股价修复。","market":"us","thumbnail":"https://community-static.tradeup.com/news/95b2b20b201e3eada64180b0770a622f","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/95b2b20b201e3eada64180b0770a622f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"一周美股牛榜 | 遭强生收购，Intra-Cellular飙33%；比特币狂飙，MicroStrategy涨21%；SoFi涨17%，小鹏涨16%","news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITCI","SOFI","HOOD","CVNA","JD","XPEV","BLDR","URI","MSTR"],"gpt_icon":1},{"id":"2503384652","title":"开年第一笔重磅并购，1000亿买神药","url":"https://stock-news.laohu8.com/highlight/detail?id=2503384652","media":"投中网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503384652?lang=zh_cn&edition=full","pubTime":"2025-01-15 13:30","pubTimestamp":1736919006,"startTime":"0","endTime":"0","summary":"仅仅两个月后，2019年12月20日，lumateperone获美国FDA批准用于治疗精神分裂症，品牌名为Caplyta。因此，自获批上市以来Caplyta大受医生欢迎，销售额增长非常迅猛，2020年2281万美元，2021年8380万美元，2022年2.5亿美元，2023年4.64亿美元。如果获批，Caplyta将成为15年来第一个获批用于治疗重度抑郁症和双相I型和II型抑郁症的新药。仅在美国就有大约240万成年人患有精神分裂症，610万成年人患有双相情感障碍，2100万成年人患有重度抑郁症，600万成年人患有阿尔茨海默病。","market":"us","thumbnail":"https://static.tigerbbs.com/940afc64cbd7527aa88ffa85143b29c9","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/940afc64cbd7527aa88ffa85143b29c9"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://mp.weixin.qq.com/s/A0_DP2JtXQsm58rpln_dog","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tzw","symbols":["ITCI","JNJ"],"gpt_icon":1},{"id":"2503586506","title":"Piper Sandler：下调Intra-Cellular Therapies(ITCI.US)评级，由增持调整至中性评级, 目标价由107.00美元调整至132.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503586506","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503586506?lang=zh_cn&edition=full","pubTime":"2025-01-15 00:42","pubTimestamp":1736872922,"startTime":"0","endTime":"0","summary":"Piper Sandler：下调Intra-Cellular Therapies(ITCI.US)评级，由增持调整至中性评级, 目标价由107.00美元调整至132.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/15004247459063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ITCI"],"gpt_icon":0},{"id":"1175027291","title":"美股制药巨头并购热潮再起！SAGE涨超36%、ITCI涨超34%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175027291","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175027291?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:47","pubTimestamp":1736779628,"startTime":"0","endTime":"0","summary":"1月13日，美股制药巨头并购热潮再起！Sage盘前涨超32%，美国制药商百健上周五宣布拟溢价30%收购剩余股份；Intra-Cellular Therapies盘前续涨超21%，该股上周五大涨近15%，消息称$强生(JNJ)$公司正洽谈对其进行收购。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SAGE","ITCI"],"gpt_icon":0},{"id":"2503583084","title":"Intra-Cellular Therapies Inc.股价飙升34.76% 市值涨47.11亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503583084","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503583084?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:32","pubTimestamp":1736778745,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时32分，Intra-Cellular Therapies Inc.股票出现波动，股价急速拉升34.76%。Intra-Cellular Therapies Inc.股票所在的制药行业中，整体跌幅为0.57%。其相关个股中，Intra-Cellular Therapies Inc.、Citius Oncology, Inc.、Im Cannabis Corp.涨幅较大，Intra-Cellular Therapies Inc.、Cbdmd, Inc.、大自然药业较为活跃，换手率分别为4.05%、3.33%、0.86%，振幅较大的相关个股有Sunshine Biopharma Inc.、Painreform Ltd.、Petros Pharmaceuticals, Inc.，振幅分别为99.66%、98.89%、7.71%。Intra-Cellular Therapies Inc.公司简介：Intra-Cellular Therapies Inc是一家开发治疗中枢神经系统疾病新药的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223225aba930da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223225aba930da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU0109394709.USD","LU0889565916.HKD","LU0053671581.USD","ITCI","LU0320765992.SGD","LU0106261612.USD","LU0012050646.USD"],"gpt_icon":0},{"id":"2503094863","title":"金十数据整理：每日美股市场要闻速递（1月13日 周一）","url":"https://stock-news.laohu8.com/highlight/detail?id=2503094863","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503094863?lang=zh_cn&edition=full","pubTime":"2025-01-13 21:05","pubTimestamp":1736773547,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["IE00B42XCP33.USD","AAPL","LU0128525929.USD","BK5011","IE000M9KFDE8.USD","DEI","IE0004086264.USD","BK4575","LU0321505868.SGD","LU2087625088.SGD","SG9999015341.SGD","LU1201861249.SGD","ITCI","AMZN","MACW.SI","GSK","LU0738911758.USD","LU0868494617.USD","BK4576","BK4588","LU1366333091.USD","MRNA","X","USAW.SI","LU2505996681.GBP","JNJ","LU1003077747.HKD","IE00B1BXHZ80.USD","LU1815333072.USD","SG9999004303.SGD","LU1778281490.HKD","SG9999017495.SGD","DB","BK4223","LU1674673691.USD","LU2089984988.USD","LU2362540622.SGD","LU0353189763.USD","SG9999015978.USD","LU2430703251.USD","GSK.UK","LU0058720904.USD","LU0289739699.SGD","IE00BMPRXN33.USD","IE00B3S45H60.SGD","SG9999014575.USD","LU2191332357.HKD","LU1814569148.SGD","LU0302445910.USD","LU2360106780.USD"],"gpt_icon":0},{"id":"2503305182","title":"强生(JNJ.US)以每股132美元现金收购Intra-Cellular(ITCI.US) 扩大精神疾病药物组合","url":"https://stock-news.laohu8.com/highlight/detail?id=2503305182","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503305182?lang=zh_cn&edition=full","pubTime":"2025-01-13 20:30","pubTimestamp":1736771422,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，强生已同意以每股132.00美元的现金收购生物制药公司Intra-Cellular Therapies的所有流通股，总股权价值约为146亿美元。受此消息提振，截至发稿，Intra-Cellular Therapies周一美股盘前暴涨近36%。这笔交易预计将于今年晚些时候完成，但需获得相关监管部门、Intra-Cellular Therapies股东的批准以及其他常规成交条件。这笔交易加强了强生的神经系统疾病产品组合。资料显示，Intra-Cellular Therapies专注于开发和商业化中枢神经系统疾病治疗方法。此外，Intra-Cellular Therapies开发的Lumateperone是一种口服非典型抗精神病药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1237022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ITCI","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","LU1914381329.SGD","BK4592","BK4581","LU1023059063.AUD","IE0002141913.USD","LU1894683348.USD","LU1674673428.USD","LU1162221912.USD","LU2347655156.SGD","LU1929549753.HKD","LU0795875086.SGD","IE00B7SZLL34.SGD","LU0203347892.USD","IE00BDGV0183.EUR","SG9999002224.SGD","LU0122379950.USD","BK4588","IE00B4R5TH58.HKD","LU1244550221.USD","LU1244550494.USD","IE0009355771.USD","LU1267930813.SGD","LU1674673691.USD","LU2133065610.SGD","IE00B1BXHZ80.USD","BK4534","BK4532","LU0234570918.USD","BK4533","BK4504","IE00BJT1NW94.SGD","LU1732800096.USD","SG9999002232.USD","LU0109394709.USD","LU0795875169.SGD","LU0345769631.USD","LU1430594728.SGD","SG9999001440.SGD","BK4550","IE00B42XCP33.USD","LU0203345920.USD","BK4559","LU0106261612.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","JNJ","LU1244550577.SGD"],"gpt_icon":0},{"id":"2503532208","title":"传强生(JNJ)拟收购神经科学制药商Intra-Cellular Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2503532208","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503532208?lang=zh_cn&edition=full","pubTime":"2025-01-13 16:27","pubTimestamp":1736756873,"startTime":"0","endTime":"0","summary":"金吾财讯 | 知情人士表示，强生(JNJ)据报准备出价100亿美元收购专注于治疗中枢神经系统疾病的生物制药公司Intra-Cellular Therapies(ITCI)，双方最早可能在本周达成协议，尽管谈判仍在进行中，但可能不会达成协议，也可能出现其他竞购者。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/ZmY2NTQyNTc0MzU2NTg=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZmY2NTQyNTc0MzU2NTg=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"284226","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051811.HKD","LU0234570918.USD","SG9999001440.SGD","LU2089984988.USD","LU1778281490.HKD","LU0795875169.SGD","BK4592","LU0640476718.USD","BK4532","LU1244550494.USD","LU1032955483.USD","LU1057294990.SGD","IE00BGHQF631.EUR","IE0009355771.USD","LU1066051225.USD","SG9999002232.USD","LU0234572021.USD","BK4568","JNJ","BK1191","IE00B4R5TH58.HKD","LU1914381329.SGD","IE00B1BXHZ80.USD","LU1674673428.USD","BK4007","LU2133065610.SGD","IE00BJJMRZ35.SGD","LU0058720904.USD","IE0002270589.USD","IE00BJT1NW94.SGD","LU0114720955.EUR","SG9999002224.SGD","LU1506573853.SGD","LU0320765646.SGD","LU1280957306.USD","BK4588","LU0889566641.SGD","LU1894683264.USD","IE00B42XCP33.USD","LU0882574055.USD","IE00B3PB1722.GBP","LU0122379950.USD","LU1929549753.HKD","LU1162221912.USD","LU1196500208.SGD","LU1732799900.SGD","LU1032466523.USD","ITCI","LU0912757837.SGD","01477"],"gpt_icon":0},{"id":"2503196753","title":"医疗并购热潮再起！传强生洽购百亿市值生物制药新星Intra-Cellular","url":"https://stock-news.laohu8.com/highlight/detail?id=2503196753","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503196753?lang=zh_cn&edition=full","pubTime":"2025-01-13 14:00","pubTimestamp":1736748019,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据知情人士透露，强生公司正在洽谈收购专注于治疗中枢神经系统疾病的生物制药公司Intra-Cellular Therapies Inc.，双方最早可能在本周达成协议，尽管谈判仍在进行中，但可能不会达成协议，也可能出现其他竞购者。对此，强生公司的一位代表拒绝发表评论，而Intra-Cellular的发言人未能立即联系到发表评论。此前，强生公司剥离了消费者健康部门，并以131亿美元收购了心脏设备制造商Shockwave Medical，现在又重新发起攻势。","market":"us","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1236521.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"医疗并购热潮再起！传强生洽购百亿市值生物制药新星Intra-Cellular","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1929549753.HKD","IE00B1BXHZ80.USD","LU1914381329.SGD","BK4532","BK4581","IE00B42XCP33.USD","LU2133065610.SGD","BK4504","LU0234572021.USD","LU0345770993.USD","LU1057294990.SGD","LU2089984988.USD","LU1430594728.SGD","LU1244550577.SGD","LU0345769128.USD","LU1244550221.USD","LU2468319806.SGD","IE00B2B36J28.USD","IE0002141913.USD","LU1066051498.USD","LU0203345920.USD","LU1778281490.HKD","LU1221951129.SGD","IE0002270589.USD","LU1032955483.USD","LU0889566641.SGD","LU1066051225.USD","LU1894683264.USD","LU1023059063.AUD","IE00BVYPNV92.GBP","LU1732800096.USD","LU0345770308.USD","IE000M9KFDE8.USD","BK4559","IE00B3PB1722.GBP","LU1280957306.USD","LU0122379950.USD","JNJ","IE00BJJMRZ35.SGD","IE00BVYPNW00.USD","IE00BSNM7G36.USD","LU1894683348.USD","LU1267930813.SGD","LU0345769631.USD","LU2347655156.SGD","IE00B4R5TH58.HKD","ITCI","SG9999002224.SGD","IE0009355771.USD","BK4550"],"gpt_icon":1},{"id":"2503343364","title":"140亿美元！强生拟收购Intra-Cellular","url":"https://stock-news.laohu8.com/highlight/detail?id=2503343364","media":"Medaverse","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503343364?lang=zh_cn&edition=full","pubTime":"2025-01-13 10:50","pubTimestamp":1736736655,"startTime":"0","endTime":"0","summary":"1月13日，强生公司正在探索收购Intra-Cellular Therapies的可能性，一家专注于中枢神经系统疾病治疗的生物制药公司。此举可能是一年多来最大的生物技术交易，Intra-Cellular的市值在最近飙升后约为100亿美元。1月10日，Intra-Cellular已与Sandoz达成和解协议，解决与CAPLYTA有关的专利诉讼。根据法律规定，Intra-Cellular Therapies将向美国联邦贸易委员会和美国司法部提交协议。Intra-Cellular Therapies对其他方提起的类似专利诉讼仍在美国新泽西州地区法院等待裁决。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113105558aba88150&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113105558aba88150&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1894683348.USD","LU0466842654.USD","LU1032955483.USD","LU0106261612.USD","LU0234572021.USD","LU0795875169.SGD","LU1732800096.USD","LU1261432733.SGD","LU1066053197.SGD","LU0203347892.USD","LU1506573853.SGD","IE00B1BXHZ80.USD","SG9999001440.SGD","BK4504","SG9999002224.SGD","LU0114720955.EUR","LU0012050646.USD","BK4532","LU0795875086.SGD","LU0792757196.USD","LU0912757837.SGD","LU0234570918.USD","LU2089984988.USD","LU1221951046.USD","IE00B42XCP33.USD","LU1057294990.SGD","IE0002141913.USD","LU1221951129.SGD","LU1244550577.SGD","LU0109394709.USD","IE00BDGV0183.EUR","ITCI","LU1778281490.HKD","BK4007","LU1066051225.USD","BK4588","IE00BJT1NW94.SGD","LU1196500208.SGD","LU0098860793.USD","LU2347655156.SGD","IE0034235303.USD","LU1244550221.USD","BK4550","IE00B4R5TH58.HKD","BK4533","LU0320765992.SGD","LU0889566641.SGD","JNJ","LU1267930813.SGD","IE00BGHQF631.EUR"],"gpt_icon":0},{"id":"1146147450","title":"美股夜盘 | 量子计算概念走低，Rigetti跌超8%；制药公司Intra-Cellular续涨超6%，获强生竞价收购","url":"https://stock-news.laohu8.com/highlight/detail?id=1146147450","media":"老虎资讯综合","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146147450?lang=zh_cn&edition=full","pubTime":"2025-01-13 09:09","pubTimestamp":1736730549,"startTime":"0","endTime":"0","summary":"本周一（1月13日）美股盘前时段，量子计算概念股普遍走低， $Rigetti Computing(RGTI)$ 跌近9%， $D-Wave Quantum Inc.(QBTS)$ 跌超6%， $IONQ Inc.(IONQ)$ 跌超3%：生物制药公司Intra-Cellular续涨超6%，上周五已涨近15%，获强生竞价收购：","market":"us","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"美股夜盘 | 量子计算概念走低，Rigetti跌超8%；制药公司Intra-Cellular续涨超6%，获强生竞价收购","news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QMCO","QBTS","RGTI","IONQ","ITCI"],"gpt_icon":0},{"id":"1135893090","title":"消息称强生公司正洽谈收购Intra-Cellular，后者市值约100亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135893090","media":"Wind","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135893090?lang=zh_cn&edition=full","pubTime":"2025-01-13 07:58","pubTimestamp":1736726316,"startTime":"0","endTime":"0","summary":"据知情人士透露，强生公司正在洽谈收购专注于治疗中枢神经系统疾病的生物制药公司Intra-Cellular Therapies，交易最快本周达成。不过，虽然讨论仍在进行，但也可能不会达成协议，而且还可能出现其他收购者。Intra-Cellular股价在过去12个月上涨约40%，市值约为100亿美元。","market":"us","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wx.wind.com.cn/shareweb/index.html?globalsharecode=3196377950546599936#/preview","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"wind","symbols":["JNJ","ITCI"],"gpt_icon":0},{"id":"2503767318","title":"强生探讨竞购生物制药公司Intra-Cellular Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2503767318","media":"界面","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503767318?lang=zh_cn&edition=full","pubTime":"2025-01-13 07:40","pubTimestamp":1736725246,"startTime":"0","endTime":"0","summary":"1月13日消息，知情人士称，强生公司正在探索收购一家生物制药公司Intra-Cellular Therapies。根据LSEG的数据，Intra-Cellular的市值约为100亿美元。知情人士称，谈判仍在进行中，交易还不确定，并补充说还可能出现其他潜在的收购者。（彭博）","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113074046aba84cd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113074046aba84cd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0034235303.USD","LU0889565916.HKD","BK4559","LU0640476718.USD","LU1162221912.USD","LU1674673691.USD","BK4585","LU1585245621.USD","LU0795875086.SGD","IE00B2B36J28.USD","JNJ","LU1066051225.USD","SG9999002232.USD","IE00B19Z3B42.SGD","LU2602419157.SGD","LU0882574055.USD","LU1023059063.AUD","BK4588","LU0889566641.SGD","LU1066051811.HKD","LU1074936037.SGD","LU2089984988.USD","LU1732799900.SGD","ITCI","SG9999001440.SGD","LU1244550494.USD","LU1244550221.USD","BK4533","BK4504","BK4568","LU0058720904.USD","LU0792757196.USD","LU1674673428.USD","LU1506573853.SGD","IE0002270589.USD","LU1059921491.USD","BK4007","LU0345769128.USD","LU0345770308.USD","IE00BJJMRZ35.SGD","BK4550","SG9999002224.SGD","IE00BSNM7G36.USD","LU2347655156.SGD","LU1894683348.USD","LU1196500208.SGD","LU0345769631.USD","LU0203345920.USD","LU0320765992.SGD","LU0012050646.USD"],"gpt_icon":0},{"id":"2502846862","title":"Intra-Cellular Therapies Inc.盘中异动 股价大涨7.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502846862","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2502846862?lang=zh_cn&edition=full","pubTime":"2025-01-10 22:31","pubTimestamp":1736519512,"startTime":"0","endTime":"0","summary":"北京时间2025年01月10日22时31分，Intra-Cellular Therapies Inc.股票出现波动，股价大幅拉升7.81%。Intra-Cellular Therapies Inc.股票所在的制药行业中，整体跌幅为0.05%。其相关个股中，Intra-Cellular Therapies Inc.、Pacira Biosciences, Inc.、Kamada Ltd.涨幅较大，大自然药业、Biofrontera Inc.、Cbdmd, Inc.较为活跃，换手率分别为5.98%、1.69%、1.13%，振幅较大的相关个股有Alpha Teknova, Inc.、Cbdmd, Inc.、Intra-Cellular Therapies Inc.，振幅分别为5.95%、3.52%、2.98%。Intra-Cellular Therapies Inc.公司简介：Intra-Cellular Therapies Inc是一家开发治疗中枢神经系统疾病新药的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110223152aba60281&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110223152aba60281&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","LU0012050646.USD","ITCI","LU0106261612.USD","LU0320765992.SGD","LU0053671581.USD","BK4007","LU0109394709.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.intracellulartherapies.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0032},{"period":"3month","weight":0.0449},{"period":"6month","weight":0.6833},{"period":"1year","weight":0.7195},{"period":"ytd","weight":0.5789}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Intra-cellular Therapies, Inc.于2001年5月22日在美国特拉华州注册成立，并于2002年6月开始运营。公司的创立旨在开发药物用于神经和精神疾病的治疗。 ITI公司是一家生物制药公司，专注于创新和发展临床的小分子药物，来改善针对中枢神经系统内精神障碍缺医少药的医疗条件。公司主导产品， ITI- 007 ，临床发展为治疗精神分裂症一流药物。目前用于治疗精神分裂症的药物也没有完全解决中枢神经系统疾病的一系列症状。这些现有的药物也被他们强大的副作用限制。 ITI- 007是用来治疗很多症状，包括急性和残余精神分裂症，具有改进后的安全性和耐受性。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.006726},{"month":2,"riseRate":0.666667,"avgChangeRate":0.026013},{"month":3,"riseRate":0.5,"avgChangeRate":0.017817},{"month":4,"riseRate":0.5,"avgChangeRate":-0.004555},{"month":5,"riseRate":0.545455,"avgChangeRate":0.066827},{"month":6,"riseRate":0.727273,"avgChangeRate":0.058875},{"month":7,"riseRate":0.272727,"avgChangeRate":-0.070967},{"month":8,"riseRate":0.272727,"avgChangeRate":0.02247},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.004794},{"month":10,"riseRate":0.454545,"avgChangeRate":0.032707},{"month":11,"riseRate":0.545455,"avgChangeRate":0.035458},{"month":12,"riseRate":0.636364,"avgChangeRate":0.302874}],"exchange":"NASDAQ","name":"Intra-Cellular Therapies Inc.","nameEN":"Intra-Cellular Therapies"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Intra-Cellular Therapies Inc.(ITCI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Intra-Cellular Therapies Inc.(ITCI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Intra-Cellular Therapies Inc.,ITCI,Intra-Cellular Therapies Inc.股票,Intra-Cellular Therapies Inc.股票老虎,Intra-Cellular Therapies Inc.股票老虎国际,Intra-Cellular Therapies Inc.行情,Intra-Cellular Therapies Inc.股票行情,Intra-Cellular Therapies Inc.股价,Intra-Cellular Therapies Inc.股市,Intra-Cellular Therapies Inc.股票价格,Intra-Cellular Therapies Inc.股票交易,Intra-Cellular Therapies Inc.股票购买,Intra-Cellular Therapies Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Intra-Cellular Therapies Inc.(ITCI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Intra-Cellular Therapies Inc.(ITCI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}